INTEGRA LIFESCIENCES HOLDINGS (IART) Company Report

CEO Mojdeh Poul acknowledged significant operational and execution challenges, particularly concerning the Quality Management System transformation and supply chain operations, which are deeper and broader than initially anticipated. The company initiated a Compliance Master Plan in mid-2024 to establish a harmonized quality management system across its global footprint.
The new Braintree manufacturing facility is expected to be operational by the end of June 2026, with the goal of bringing SurgiMend back to market by Q4 2026. Additionally, PriMatrix and Durepair were relaunched in early October 2025, nearly a year ahead of schedule, with early indications for PriMatrix being very positive.
Integra LifeSciences' top financial priorities through the end of 2026 include debt reduction and leverage improvement, driven by enhanced operational cash flow, improved EBITDA, and aggressive working capital management. A margin expansion program is expected to deliver $25-$30 million in savings in 2026.
The company has paused M&A activities to focus on internal improvements and debt reduction, with acquisitions expected to be considered beyond 2026.

1 day ago

Transcript

Integra LifeSciences Outlines Operational Turnaround and Growth Strategy

IART

New Projects/Investments

Product Launch

Guidance Update

Integra LifeSciences is implementing a Quality Management System (QMS) transformation and a Compliance Master Plan to address significant operational and execution challenges.
The new Braintree manufacturing facility is expected to be operational by June 2026, aiming to reintroduce SurgiMend to the market by Q4 2026.
PriMatrix and Durepair were relaunched in early October 2025, ahead of schedule, with positive early reception for PriMatrix.
Key strategic priorities through 2026 include debt reduction, supply resiliency, and execution excellence, supported by a margin improvement plan targeting $25-$30 million in savings for 2026.

1 day ago

Transcript

Integra LifeSciences Receives FDA Clearance for CUSA® Clarity System in Cardiac Surgeries

IART

Product Launch

New Projects/Investments

Integra LifeSciences (Nasdaq: IART) announced it received FDA 510(k) clearance for its CUSA® Clarity Ultrasonic Surgical Aspirator System for use in cardiac surgeries.
The clearance specifically allows for the debridement of unwanted tissue during cardiac surgeries, including valve replacement and repair.
This expansion is considered the "next pivotal expansion" for the ultrasonic surgical aspirator system, enhancing the company's ability to provide advanced surgical solutions.
The company plans to spotlight the CUSA Clarity system at the American Association for Thoracic Surgeon Mitral Valve Conclave on December 11 and 12, 2025.

Nov 11, 2025, 9:15 PM

Press Release

Integra LifeSciences Reports Q3 2025 Results and Updates Full-Year Guidance

IART

Earnings

Guidance Update

Product Launch

Integra LifeSciences reported Q3 2025 revenue of $402 million, representing 5% organic growth year-over-year, which was below guidance, while adjusted EPS of $0.54 exceeded the top end of their guidance range.
The company revised its full-year 2025 revenue guidance to a range of $1.62 billion to $1.64 billion and adjusted EPS guidance to $2.19 to $2.24, reflecting lower Q3 revenue and updated Q4 assumptions.
Primatrix and DuraPair were relaunched in Q4 2025, almost a year ahead of previously expected timelines, due to a new third-party supply agreement as part of a dual sourcing strategy.
Operational improvements include a 50% increase in Integra Skin manufacturing yields and a two-and-a-half times increase in inventory levels since January, with the Braintree facility on track to resume production in June 2026.
A cost reduction program is underway, expected to yield $25 to $30 million in savings in 2026 through COGS improvement, third-party spend reduction, and operating model efficiencies.

Oct 30, 2025, 12:30 PM

Transcript

Integra LifeSciences Holdings Corporation (IART) Announces Q3 2025 Results

IART

Earnings

Guidance Update

Product Launch

Integra LifeSciences Holdings Corporation reported Q3 2025 total revenues of $402.1 million, reflecting a 5.6% reported growth and 5.0% organic growth, which was below expectations due to a CSS supply interruption.
The company delivered adjusted earnings per diluted share of $0.54 for Q3 2025, surpassing expectations and representing a 31.7% increase compared to Q3 2024.
Adjusted EBITDA margin improved by 330 basis points to 19.5% in Q3 2025 compared to Q3 2024.
IART is updating its 2025 guidance to reflect third-quarter performance and expects to realize $25 to $30 million in cost savings in 2026 through a margin expansion program. Operationally, PriMatrix and Durepair were relaunched in Q4 2025 ahead of schedule, and the Braintree facility is on track to resume production in June 2026 to support the planned relaunch of SurgiMend in Q4 2026.

Oct 30, 2025, 12:30 PM

Presentation

Integra LifeSciences Reports Third Quarter 2025 Financial Results and Updates Guidance

IART

Earnings

Guidance Update

Management Change

Integra LifeSciences reported third quarter 2025 revenues of $402.1 million, an increase of 5.6% on a reported basis and 5.0% organically compared to the prior year.
For Q3 2025, the company reported a GAAP net loss of $(0.07) per diluted share, while adjusted earnings per diluted share were $0.54.
The company is revising its 2025 full-year revenue guidance to a range of $1.620 billion to $1.640 billion and adjusted earnings per diluted share guidance to $2.19 to $2.24.
Integra LifeSciences also announced the relaunch of PriMatrix® and Durepair® ahead of schedule and the appointment of Dr. Raymond Turner as chief medical officer.

Oct 30, 2025, 10:15 AM

8-K

Integra LifeSciences Reports Third Quarter 2025 Financial Results and Updates 2025 Guidance

IART

Earnings

Guidance Update

Product Launch

Integra LifeSciences reported third quarter 2025 revenues of $402.1 million, an increase of 5.6% on a reported basis and 5.0% organically compared to the prior year.
The company achieved adjusted earnings per diluted share of $0.54 in Q3 2025, compared to $0.41 in the prior year, while GAAP earnings per diluted share were $(0.07).
Integra LifeSciences successfully relaunched PriMatrix® and Durepair® ahead of schedule through a dual sourcing supply strategy.
The company revised its full-year 2025 revenue guidance to a range of $1.620 billion to $1.640 billion and expects adjusted EPS in the range of $2.19 to $2.24 per share.

Oct 30, 2025, 10:00 AM

Press Release

Integra LifeSciences Discusses Operational Challenges, Financial Outlook, and Growth Drivers

IART

Guidance Update

New Projects/Investments

Debt Issuance

Integra LifeSciences updated its 2025 gross margin guidance in Q2, now expecting a decline of 300 basis points versus 2024, an additional 100 basis points compared to Q1 expectations, primarily due to costs from the MetaHunting product recall.
The company has launched a profitability initiative aiming for $25 million to $30 million in annualized savings by 2026, focusing on operational improvements and OpEx management, with P&L impact expected in the second half of 2026.
Management expects 2025 to be the peak year for ship hold impact and anticipates growth in 2026 driven by strengthened quality management systems, increased supply reliability, and the benefits of the margin expansion program.
Near-term capital allocation priority remains debt reduction, with leverage at 4.5 times at the end of Q2 2025, within the 5x maximum allowable ratio. M&A is not a near-term priority.
Key growth drivers for the next two to three years include stabilizing supply, reintroducing Primatrix and Surgemend (with Braintree facility operationalization targeted for 2026), and international expansion.

Sep 3, 2025, 6:06 PM

Earnings Transcripts

Quarterly earnings call transcripts for INTEGRA LIFESCIENCES HOLDINGS.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Mojdeh Poul say about margins?What are INTEGRA LIFESCIENCES HOLDINGS's strategic priorities?How is INTEGRA LIFESCIENCES HOLDINGS positioned vs competitors?How did INTEGRA LIFESCIENCES HOLDINGS do last quarter?

Let Fintool AI Agent track INTEGRA LIFESCIENCES HOLDINGS's earnings for you

Get instant analysis when filings drop